Form 4: Avidity Biosciences CEO Sells Shares for Tax Obligations

Avidity Biosciences' President and CEO, Sarah Boyce, sold 14,387 shares of common stock at $72.45 per share to cover tax withholding obligations related to RSU vesting.

Summary

• Sarah Boyce, President and CEO, and a Director of Avidity Biosciences, Inc., reported transactions involving the company's common stock.
• On January 21, 2026, Boyce sold a total of 14,387 shares of Avidity Biosciences common stock.
• The sales consisted of 6,394 shares and 7,993 shares, both at a price of $72.45 per share.
• These sales were non-discretionary "sell-to-cover" transactions, mandated by the issuer's equity incentive plans to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units (RSUs) on January 20, 2026.
• The transactions were executed pursuant to a Rule 10b5-1 plan, indicating they were pre-scheduled.
• Following these transactions, Sarah Boyce beneficially owns 269,007 shares of Avidity Biosciences common stock directly.

Sentiment

Score: 5

Explanation: The transaction is neutral. It's a routine, non-discretionary sale to cover tax obligations from RSU vesting, executed under a Rule 10b5-1 plan. It does not indicate any change in management's outlook or confidence in the company.

Positives

• The transaction was non-discretionary and pre-planned under a Rule 10b5-1 plan, indicating no new negative sentiment from management.
• The sale was solely to cover tax withholding obligations, a standard practice for RSU vesting.

Future Outlook

No forward-looking statements or guidance were provided in this Form 4 filing, as it pertains to a past transaction.

Management Comments

• The sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a 'sell-to-cover' transaction and does not represent a discretionary trade by the Reporting Person.
• The Reporting Person has executed an instruction letter for the automatic sale of such 'sell-to-cover' shares, intended to satisfy the affirmative defense conditions of Rule 10b5-1.

Industry Context

This Form 4 filing details a routine insider transaction common across all industries, particularly for executives receiving equity compensation. The 'sell-to-cover' mechanism is a standard practice in many public companies to manage tax liabilities associated with RSU vesting, and does not reflect specific industry trends for biotechnology.

Comparison to Industry Standards

• The 'sell-to-cover' transaction for tax obligations upon RSU vesting is a standard and widely accepted practice in corporate compensation across various industries, including biotechnology. Companies like Moderna (MRNA) or BioNTech (BNTX) often see similar Form 4 filings from executives for tax-related sales following equity awards.
• The use of a Rule 10b5-1 plan for such transactions is also a common corporate governance best practice, demonstrating pre-planning and mitigating concerns about insider trading based on material non-public information.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary transaction for tax purposes and does not signal a change in management's view of the company's prospects. The number of shares sold is a small fraction of the total outstanding shares.
• Employees: No direct impact mentioned.
• Customers/Suppliers/Creditors: No direct impact mentioned.

Next Steps

• No specific future actions or milestones are mentioned in this Form 4 filing, as it reports a completed transaction.

Key Dates

Recommendation

This Form 4 filing reports a routine, non-discretionary 'sell-to-cover' transaction by the CEO to satisfy tax obligations upon RSU vesting. Such transactions, especially when executed under a Rule 10b5-1 plan, are standard practice and do not typically reflect a change in management's sentiment or the company's fundamentals. Therefore, this specific filing alone does not provide a basis for changing an investment recommendation; a 'hold' stance is maintained pending further fundamental analysis.

Keywords

Avidity Biosciences, RNA, Sarah Boyce, Form 4, Insider Trading, Stock Sale, RSU Vesting, Tax Withholding, Rule 10b5-1, Biotechnology